Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Perrigo Adds Good Start Brand In $230M Statement On Boosting Infant Formula Production Capacity

Nov 02 2022

• By Malcolm Spicer

• Source: Shutterstock

Related Content

US FDA Requests More Information, Needs More Time To Review Birth Control OTC Switch Proposal

Oct 27 2022

Abbott Concludes Former Employees’ Allegations Concerning Michigan Formula Plant ‘Unfounded’

Oct 19 2022

Abbott US Nutrition Chief Testifies ‘Safety First’ During House Hearing On Formula Shortage

May 26 2022

Perrigo Debuts On US National Brand Stage With OTC Switch Approval For Nasonex 24HR Allergy

Mar 17 2022

US FDA Has 10 Months To Provide Answer On Perrigo/HRA OTC Oral Contraceptive Application

Jul 12 2022

Along With Sales Across Regions And Categories, Perrigo’s Labor Shortage Concerns Grow

Aug 09 2022

Perrigo Starts Supply Chain Overhaul After Filing OTC Birth Control NDA, Launching Nasonex Switch

Aug 09 2022

Perrigo Out From Under VMS Weight As IVC Lifts Private Label Profile

Jun 21 2016

Infant Formula Woes Turn Perrigo's Q2 Sour Despite Solid Americas’ OTC Sales

Aug 09 2019

Related Companies

Perrigo Company PLC

Abbott

Additional Topics

International Switzerland Europe Canada United States US States Dietary Supplements M & A Supply Chain Advertising, Marketing & Sales Business Strategies Commercial Companies Compliance Consumer Distribution FDA Ingredients Manufacturing Policy Politics Regulation Retail Safety

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window